Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Arthritis Rheum ; 65(11): 2866-75, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23897278

ABSTRACT

OBJECTIVE: We previously described a messenger RNA variant of ADAMTS4 (ADAMTS4_v1) in human synovial cell cocultures obtained from patients with osteoarthritis (OA). This RNA message has been found only in OA synovium and, if translated, would result in a protein identical to ADAMTS-4, except that the C-terminal spacer domain would be different. The purpose of this study was to determine whether ADAMTS4_v1 is translated into a protein, is expressed in vivo, and acts as a functional aggrecanase. METHODS: Polyclonal antibodies were raised against unique C-terminal sequences of ADAMTS-4_v1. An immunohistochemical study of human OA synovium was performed. A mammalian expression vector coding for FLAG-tagged human ADAMTS4 was mutated to contain the different sequences of ADAMTS4_v1, and the resultant plasmid was used to transfect HEK 293 cells. ADAMTS-4_v1 produced by these cells was purified via the FLAG epitope, and the ability of this recombinant protein to cleave aggrecan, biglycan, and decorin was investigated. RESULTS: An antibody specific for ADAMTS-4_v1 was found to bind to the synovial membrane surface on cryosections, and the protein was detected in cell lysates from synovium obtained from OA patients. The recombinant ADAMTS-4_v1 demonstrated enzyme activity toward the target substrate in a commercial aggrecanase 1 enzyme-linked immunosorbent assay and was also found to cleave aggrecan at the pathologically important Glu(373↓374) Ala aggrecanase site. CONCLUSION: ADAMTS-4_v1 is expressed as a protein in vivo in human OA synovium, functions as an aggrecanase, and cleaves other proteoglycan substrates. This splice variant may be a major contributor to loss of aggrecan from the superficial zone of OA cartilage.


Subject(s)
ADAM Proteins/genetics , ADAM Proteins/metabolism , Aggrecans/metabolism , Alternative Splicing/genetics , Osteoarthritis/genetics , Osteoarthritis/metabolism , Procollagen N-Endopeptidase/genetics , Procollagen N-Endopeptidase/metabolism , ADAM Proteins/immunology , ADAMTS4 Protein , Aggrecans/chemistry , Autoantibodies/immunology , Cells, Cultured , Coculture Techniques , HEK293 Cells , Humans , Osteoarthritis/immunology , Procollagen N-Endopeptidase/immunology , Protein Structure, Tertiary , RNA, Messenger/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Substrate Specificity , Synovial Membrane/cytology , Synovial Membrane/physiology
2.
Expert Opin Ther Targets ; 15(12): 1355-68, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22087738

ABSTRACT

INTRODUCTION: The success of targeted biologic therapy against rheumatoid arthritis has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis, in the hope of defining novel therapeutic targets. Osteoarthritis has long been thought of mainly as a degenerative disease of cartilage, with secondary bony damage and osteophytes. However, in recent years, the importance of the synovium, and in particular the synovial macrophages, has been highlighted in both in vitro and in vivo studies. AREAS COVERED: The recent progress in osteoarthritis drug discovery, particularly with regard to the search for therapeutic targets for this disease and the development of disease-modifying anti-osteoarthritic drugs is critically assessed. Some important recent research with regard to possible therapeutic targets in osteoarthritis drug discovery is highlighted. EXPERT OPINION: The concept that synovial macrophages and macrophage-produced cytokines, may play a role in driving inflammatory and destructive signalling pathways in osteoarthritis, is of importance for drug discovery in this disease, in spite of disappointing results from early studies of anti-cytokine strategies in osteoarthritis clinical trials. There is also an abundance of potential downstream therapeutic targets in osteoarthritis, including the matrix metalloproteinases, the aggrecanases, iNOS and elements of the Wnt pathway.


Subject(s)
Drug Discovery , Osteoarthritis/drug therapy , Animals , Cytokines/immunology , Humans , Macrophages/immunology , Matrix Metalloproteinase Inhibitors , Nitric Oxide Synthase Type II/antagonists & inhibitors , Osteoarthritis/immunology , Osteoarthritis/pathology , Synovial Membrane/immunology , Synovial Membrane/pathology , Wnt Signaling Pathway/immunology
3.
Curr Drug Targets ; 11(5): 576-85, 2010 May.
Article in English | MEDLINE | ID: mdl-20199392

ABSTRACT

The great success of targeted biologic therapy against rheumatoid arthritis (RA) in recent years has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis (OA) in the hope of defining novel therapeutic targets. In contrast to RA, with its pannus and erosions, OA has long been thought of as a degenerative disease of cartilage, with secondary bony damage and osteophytes. But in recent years, the importance of the synovium, and in particular the synovial macrophages, in OA, has been highlighted in both in vitro and in vivo studies. This review will discuss the potential of synovial macrophages and their mediators, in particular the proinflammatory cytokines tumour necrosis factor alpha and interleukin-1, as potential therapeutic targets in OA.


Subject(s)
Antirheumatic Agents/therapeutic use , Drug Delivery Systems/methods , Macrophages/drug effects , Osteoarthritis/drug therapy , Synovial Membrane/drug effects , Animals , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/metabolism , Disease Models, Animal , Humans , Interleukin-1/metabolism , Macrophages/metabolism , Models, Immunological , Osteoarthritis/immunology , Osteoarthritis/metabolism , Synovial Membrane/immunology , Synovial Membrane/metabolism , Tumor Necrosis Factor-alpha/metabolism
5.
J Rheumatol ; 34(3): 523-33, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17295438

ABSTRACT

OBJECTIVE: To investigate the role of the transcription factor nuclear factor-kB (NF-kappaB) in promoting inflammatory and destructive responses in human osteoarthritis (OA) synovial fibroblasts, by assessing the effect of NF-kappaB blockade on the production of cytokines and destructive enzymes. METHODS: Infection with adenoviruses transferring the beta-galactosidase gene was used to ascertain that the OA fibroblasts could be infected (> 95%). Using an adenovirus transferring the inhibitory subunit IkappaBa, effective inhibition of NF-kappaB was achieved. The expression and production of several pro- and antiinflammatory cytokines and mediators, the major matrix metalloproteinases (MMP 1, 3, and 13), their main inhibitor tissue inhibitor of metalloproteinase-1 (TIMP-1), and the aggrecanases (ADAMTS4 and ADAMTS5) were measured by ELISA and/or reverse transcription-polymerase chain reaction, and their dependence on NF-kappaB evaluated. RESULTS: The production of interleukin 6 (IL-6), monocyte chemoattractant protein-1, and RANTES was potently inhibited by IkBa overexpression, irrespective of stimulus, but IL-8 was unaffected. The p55 soluble tumor necrosis factor (TNF) receptor was unaffected, but the p75 soluble TNF receptor was potently inhibited by IkBa overexpression. MMP-1, MMP-3, and MMP-13 were inhibited by IkappaBa overexpression, at both the mRNA and protein levels, whereas TIMP-1 was unaffected. The mRNA gene expression of ADAMTS4 was also inhibited by IkappaBa overexpression, particularly in IL-1-stimulated cells, but ADAMTS5 was unaffected. CONCLUSION: In OA synovial fibroblasts, inhibition of NF-kappaB has a beneficial effect on the balance between the expression of proinflammatory cytokines and antiinflammatory mediators. Inhibition of this transcription factor also results in the decreased expression of several destructive metalloproteinases and also the ADAMTS4 aggrecanase.


Subject(s)
ADAM Proteins/metabolism , Fibroblasts/immunology , Inflammation Mediators/metabolism , Matrix Metalloproteinases/metabolism , NF-kappa B/immunology , Osteoarthritis/physiopathology , Procollagen N-Endopeptidase/metabolism , ADAMTS4 Protein , ADAMTS5 Protein , Adenoviridae , Aged , Aged, 80 and over , Cells, Cultured , Female , Fibroblasts/enzymology , Fibroblasts/metabolism , Genetic Vectors , Humans , Male , Middle Aged , NF-kappa B/antagonists & inhibitors , Synovial Membrane/cytology , Synovial Membrane/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism
6.
Arthritis Res Ther ; 8(6): R187, 2006.
Article in English | MEDLINE | ID: mdl-17177994

ABSTRACT

There is an increasing body of evidence that synovitis plays a role in the progression of osteoarthritis and that overproduction of cytokines and growth factors from the inflamed synovium can influence the production of degradative enzymes and the destruction of cartilage. In this study, we investigate the role of synovial macrophages and their main proinflammatory cytokines, interleukin (IL)-1 and tumour necrosis factor-alpha (TNF-alpha), in driving osteoarthritis synovitis and influencing the production of other pro- and anti-inflammatory cytokines, production of matrix metalloproteinases, and expression of aggrecanases in the osteoarthritis synovium. We established a model of cultures of synovial cells from digested osteoarthritis synovium derived from patients undergoing knee or hip arthroplasties. By means of anti-CD14-conjugated magnetic beads, specific depletion of osteoarthritis synovial macrophages from these cultures could be achieved. The CD14+-depleted cultures no longer produced significant amounts of macrophage-derived cytokines like IL-1 and TNF-alpha. Interestingly, there was also significant downregulation of several cytokines, such as IL-6 and IL-8 (p < 0.001) and matrix metalloproteinases 1 and 3 (p < 0.01), produced chiefly by synovial fibroblasts. To investigate the mechanisms involved, we went on to use specific downregulation of IL-1 and/or TNF-alpha in these osteoarthritis cultures of synovial cells. The results indicated that neutralisation of both IL-1 and TNF-alpha was needed to achieve a degree of cytokine (IL-6, IL-8, and monocyte chemoattractant protein-1) and matrix metalloproteinase (1, 3, 9, and 13) inhibition, as assessed by enzyme-linked immunosorbent assay and by reverse transcription-polymerase chain reaction (RT-PCR), similar to that observed in CD14+-depleted cultures. Another interesting observation was that in these osteoarthritis cultures of synovial cells, IL-1beta production was independent of TNF-alpha, in contrast to the situation in rheumatoid arthritis. Using RT-PCR, we also demonstrated that whereas the ADAMTS4 (a disintegrin and metalloprotease with thrombospondin motifs 4) aggrecanase was driven mainly by TNF-alpha, ADAMTS5 was not affected by neutralisation of IL-1 and/or TNF-alpha. These results suggest that, in the osteoarthritis synovium, both inflammatory and destructive responses are dependent largely on macrophages and that these effects are cytokine-driven through a combination of IL-1 and TNF-alpha.


Subject(s)
Cytokines/biosynthesis , Endopeptidases/metabolism , Macrophages/metabolism , Matrix Metalloproteinases/metabolism , Osteoarthritis/metabolism , Synovial Membrane/metabolism , Aged , Aged, 80 and over , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Humans , Inflammation/metabolism , Interleukin-1beta/metabolism , Male , Middle Aged , RNA/analysis , Reverse Transcriptase Polymerase Chain Reaction , Synovial Membrane/cytology , T-Lymphocytes , Tissue Inhibitor of Metalloproteinases , Tumor Necrosis Factor-alpha/metabolism
7.
Matrix Biol ; 25(5): 317-20, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16723216

ABSTRACT

The major proteoglycan of articular cartilage aggrecan is a substrate for ADAMTS4. RT-PCR analysis of human osteoarthritic (OA) synovial co-cultures using oligonucleotide primers designed to amplify across the exon 8/9 junction of human ADAMTS4 resulted in the amplification of two products, the expected product and a smaller product missing 161 bp from the 5' end of exon 9, the result of alternative splicing in which exon 8 joins to a cryptic 3' splice site within exon 9. The protein produced would be identical to human ADAMTS4 up to Arg(696), and would have a new C-terminal domain with no commonality with the ADAMTS4 spacer domain. Changes in the C-terminal domain of ADAMTS4 may alter its substrate specificity.


Subject(s)
ADAM Proteins/genetics , Alternative Splicing , Osteoarthritis/enzymology , Osteoarthritis/genetics , Procollagen N-Endopeptidase/genetics , Synovial Membrane/enzymology , ADAM Proteins/chemistry , ADAM Proteins/metabolism , ADAMTS4 Protein , Amino Acid Sequence , Base Sequence , DNA, Complementary/genetics , Exons , Humans , In Vitro Techniques , Molecular Sequence Data , Procollagen N-Endopeptidase/chemistry , Procollagen N-Endopeptidase/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence Homology, Amino Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...